BEAM · Beam Therapeutics Inc.
Beam Therapeutics (BEAM) — clinical-stage biotech developing precision genetic medicines via base editing. This page aggregates recent SEC filings (10-Q/10-K), a short market commentary, our current sell recommendation, and active research items. Items are factual extracts from public filings and trading activity; not investment advice.
Recent proof-backed thesis calls
We highlighted multiple recent company filings (10-Qs for 2025-06-30, 2025-09-30, 2026-03-31 and the 2025 10-K). Filings show continued R&D spend, collaboration revenue variability, and an enlarged share count following a March 2025 offering. Key balance-sheet items: cash, cash equivalents and marketable securities totaled about $1.2B as of 2026-03-31, and the company reported continued operating losses and an accumulated deficit.
A Steve Horvath post highlights a longevity preprint claiming that over-expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene-expression-based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early-stage preprint, in vitro
The source is a one-line conceptual statement about aging as a drift from optimal gene expression. It provides no company, product, catalyst, timing, or investable details, so it is not directly actionable for trading without additional context (e.g., specific targets, modalities, clinical readouts, or firms).
The provided excerpt of Beam Therapeutics’ (BEAM) 10-Q for the quarter ended 2026-03-31 contains only the cover page/filing compliance information (issuer details, exchange listing, checkboxes for filing status). It does not include financial statements, MD&A, cash runway, guidance, pipeline updates, risk factors, or any quantitative/disclosive items that would support a tradable view.
Short listing for a YouTube interview filmed at the 2026 Abundance360 Summit with Ben Lamm (Colossal) titled “AI + Synthetic Biology: The Most Transformative Technology in Human History.” The listing notes the video but the transcript could not be retrieved. Content likely promotes Colossal’s synthetic biology/de‑extinction work and argues AI+synthbio is transformational. No new corporate filings, financing, or measurable operational updates are present in the item.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
The provided excerpt is only the cover/boilerplate portion of Beam Therapeutics’ (BEAM) 10-K for FY ended 2025-12-31 (listing details, exchange, reporting status). It contains no financial statements, MD&A, risk factor changes, guidance, pipeline updates, cash runway, or material events; therefore it is not directly actionable for trading based on the text supplied.
The provided excerpt is only the cover/header portion of Beam Therapeutics’ 10-Q (Form type, period ended, listing info, compliance checkboxes) and contains no financial results, guidance, pipeline/clinical updates, risks, or MD&A details. As-is, it does not support a directional trading thesis beyond noting a routine filing.
The provided text is only the cover/header portion of Beam Therapeutics’ Form 10‑Q for the quarter ended 2025‑06‑30. It contains no financial statements, guidance, clinical/program updates, cash runway, risk factor changes, or other performance details, so it offers limited actionable trading signal beyond confirming BEAM is a Nasdaq-listed SEC reporting issuer that filed required reports.
Latest market-close explanation
Latest trading note: BEAM ticked up to $31.85 (+0.85%) on a ~62% volume increase without company-specific news. Price tested the $32.5 area and faded into the close — a pattern consistent with flow-driven sector interest or technical probing rather than a fundamental breakout. Watch for follow-through above ~$32.5 on sustained volume or a fade below ~$31.
What most likely happened - No company-specific news or earnings to drive the move. With the stock closing down 3.1% on 40% lower-than-normal volume, the simplest explanation is light-volume profit-taking or repositioning rather than a fresh adverse development. - Price action (intraday low undercut the open and close below yesterday’s close) signals mild selling pressure, but the low volume reduces the conviction that this is the start of a larger downtrend. What to watch next - Any company updates: clinical data releases, regulatory communications, partnership deals, or SEC filings. Those remain the likeliest catalysts to move BEAM materially. - Biotech sector tone and headline risk (FDA decisions, sector ETFs) — broad sector weakness could push BEAM lower even without company news. - Volume on follow-up sessions: a similar decline on rising volume would confirm meaningful distribution; a rebound on higher volume would indicate buyers stepping in. - Short interest and options activity: spikes in shorting or large put buying can amplify downside if sector sentiment sours. - Upcoming calendar items: trial milestones or investor-day events (check BEAM’s clinical/regulatory calendar). Note: internal research snippets you provided relate to photonics/optics and do not appear relevant to Beam Therapeutics’ genome-editing business; no link to today’s move is evident.
Current stance
Current recommendation: sell. Rationale is filing- and results-driven: recent periodic reports show persistent losses, ongoing cash burn from R&D, and dilution events (equity offering). Market activity and filings imply heightened financing and execution risk; see detailed explanations below.
- sell via BEAM 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- sell via BEAM 10-K report for 2025-12-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- sell via BEAM 10-Q report for 2025-09-30 from https://www.sec.gov/edgar/search/ (confidence 0.60)
Top authors on this asset
Active and historical ticker theses
Active research items include routine SEC periodic reports (10-Qs and 10-K) that supply financial statements and MD&A but — in the provided excerpts — often only include cover/header pages. These filings confirm listing and reporting status but, where full statements are available, show rising operating expenses, collaboration revenue swings, and financing activity (public offering, ATM program, and a credit facility drawn in Feb 2026).
No high-conviction trade signal can be extracted from the provided 10‑Q header alone.
BEAM 10-Q report for 2025-09-30
BEAM 10-K report for 2025-12-31
BEAM 10-Q report for 2026-03-31
High-beta genetic medicine sentiment basket (theme-driven, not company-specific)
Unlock full asset monitoring
Read the cited SEC filings for full financials and risk disclosures (links available in source records). Monitor upcoming clinical or partnering announcements, SEC filings for financing activity, and volume/price action for confirmation of any trend change.